Table 3

Outcomes after 6 months of continued treatment following hospitalisation*

Pirfenidone (N=44)Placebo (N=49)Relative difference (%)p Value†
≥10% decline in FVC or death4 (9.1%)16 (32.7%)−72.20.010
No further decline in FVC‡15 (34.1%)12 (24.5%)39.20.364
Death2 (4.5%)14 (28.6%)−84.30.002
  • *All-cause hospitalisation between baseline and month 6; treatment outcomes assessed during the 6-month interval beginning with the first study visit following the date of hospitalisation.

  • †Fisher's exact test.

  • ‡Either no decline or increase in FVC.